Medifast Inc
NYSE:MED
Medifast Inc
Medifast, Inc. engages in the provision of healthy living products and programs. The company is headquartered in Owings Mills, Maryland and currently employs 984 full-time employees. The firm's operations are conducted through its subsidiaries Jason Pharmaceuticals, Inc., OPTAVIA, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Medifast Franchise Systems, Inc., Seven Crondall Associates, LLC, Corporate Events, Inc., OPTAVIA (Hong Kong) Limited, OPTAVIA (Singapore) PTE. LTD and OPTAVIA Health Consultation (Shanghai) Co., Ltd. The firm's product line includes approximately 137 consumable options, including, bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The Company, through Medifast Direct, its direct-to-consumer business unit.
Medifast, Inc. engages in the provision of healthy living products and programs. The company is headquartered in Owings Mills, Maryland and currently employs 984 full-time employees. The firm's operations are conducted through its subsidiaries Jason Pharmaceuticals, Inc., OPTAVIA, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Medifast Franchise Systems, Inc., Seven Crondall Associates, LLC, Corporate Events, Inc., OPTAVIA (Hong Kong) Limited, OPTAVIA (Singapore) PTE. LTD and OPTAVIA Health Consultation (Shanghai) Co., Ltd. The firm's product line includes approximately 137 consumable options, including, bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The Company, through Medifast Direct, its direct-to-consumer business unit.
Revenue Decline: Q4 revenue fell 36.9% year-over-year to $75.1 million, mainly due to fewer active earning coaches, but was within guidance.
Coach Productivity: Quarterly coach productivity (revenue per active earning coach) grew 6.2% year-over-year, the first positive growth since mid-2022.
Loss Per Share: Q4 loss per share was $1.65, including a $1.10 impact from a noncash deferred tax valuation allowance. Excluding this, the loss per share was $0.55, which was better than guidance.
Transformation Progress: Management highlighted completion of a major business transformation toward metabolic health, with early signs of improvement but lagging revenue recovery.
Cost Cuts: Over $30 million in targeted cost savings and restructuring were executed, helping to preserve financial flexibility.
2026 Guidance: Medifast expects full-year 2026 revenue of $270–300 million and a loss per share of $1.55–$2.75, with profitability improvements targeted for Q4 2026 and beyond.
New Product Launch: A new metabolic health-focused product line is set to launch in the back half of 2026, expected to drive future growth.
